Literature DB >> 16813905

Fate of the leftover bladder after supravesical urinary diversion for benign disease.

Tajammul Fazili1, Tahir R Bhat, Shikohe Masood, John H Palmer, G R Mufti.   

Abstract

PURPOSE: We studied the fate of the leftover bladder in patients who underwent supravesical urinary diversion without cystectomy for benign pathology.
MATERIALS AND METHODS: This retrospective study was performed in 9 males and 15 females with a median age of 59 years in whom supravesical urinary diversion was performed for various benign conditions from 1996 to 2004. These conditions were incontinence, acontractile bladder, radiation and/or hemorrhagic cystitis, and neuropathic bladder. Median followup was 48 months.
RESULTS: Of the patients 13 (54%) experienced problems with the retained bladder, 2 (8%) presented with urethral bleeding, which resolved by conservative means, and 11 (46%) had infective complications, which resolved with expectant treatment in 3 (12%). However, 8 patients (33%) had frank pyocystis and 3 (12%) were treated with the Spence procedure, which alleviated symptoms in only 1. Six patients (25%) required cystectomy.
CONCLUSIONS: In patients undergoing supravesical urinary diversion for benign disease in whom the bladder remains in situ the risks of complications related to the defunctionalized bladder are more than 50% and 25% of patients subsequently need cystectomy. These patients should be offered primary cystectomy at urinary diversion.

Entities:  

Mesh:

Year:  2006        PMID: 16813905     DOI: 10.1016/j.juro.2006.03.056

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis.

Authors:  George Goucher; Fred Saad; Himu Lukka; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2019-02       Impact factor: 1.862

Review 2.  Pyocystis: a systematic review.

Authors:  Mohamed H Kamel; Ramsey Gardner; Ali Tourchi; Karen Tart; Omer Raheem; Bradley Houston; Nabil Bissada; Rodney Davis
Journal:  Int Urol Nephrol       Date:  2017-03-07       Impact factor: 2.370

3.  Bladder augmentation and urinary diversion for neurogenic LUTS: current indications.

Authors:  Kamran P Sajadi; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

Review 4.  Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies.

Authors:  Bernadette M M Zwaans; Laura E Lamb; Sarah Bartolone; Heinz E Nicolai; Michael B Chancellor; Stangel-Wójcikiewicz Klaudia
Journal:  Int Urol Nephrol       Date:  2018-08-21       Impact factor: 2.370

5.  Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis.

Authors:  Bernadette M M Zwaans; Heinz G Nicolai; Michael B Chancellor; Laura E Lamb
Journal:  Rev Urol       Date:  2016

Review 6.  Management of radiation cystitis.

Authors:  Shaun G Smit; Chris F Heyns
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

Review 7.  Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management.

Authors:  Arun Sahai; Eduardo Cortes; Jai Seth; Muhammad Shamim Khan; Jalesh Panicker; Cornelius Kelleher; Thomas M Kessler; Clare J Fowler; Prokar Dasgupta
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 8.  [Long-term follow-up of the defunctionalized bladder after urinary diversion].

Authors:  F-C von Rundstedt; D Lazica; A S Brandt; M J Mathers; S Roth
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

9.  Carcinoma in the inactive bladder - the dilemma of the forgotten organ.

Authors:  Michał Kupś; Marcin Słojewski; Oleg Oszurek; Andrzej Sikorski
Journal:  Cent European J Urol       Date:  2012-03-19

Review 10.  Urological complications after radiation therapy-nothing ventured, nothing gained: a Narrative Review.

Authors:  Joanna Chorbińska; Wojciech Krajewski; Romuald Zdrojowy
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.